Teva’s Ajovy® FDA Filing Accepted for Pediatric Migraine Prevention
Teva Pharmaceuticals has submitted a supplemental Biologics License Application to the FDA for AJOVY (fremanezumab-vfrm) to prevent episodic migraines...
Reunion Neuroscience at ADAA 2025: Re104 for Adjustment Disorder
Reunion Neuroscience presented the design of its REKINDLE Phase 2 clinical trial, which will evaluate RE104 for treating adjustment...
Briumvi’s Impact Highlighted in Medical Journals
TG Therapeutics announced the publication of two articles, one examining the evolution of CD20 treatments for multiple sclerosis (MS)...
Rhythm’s Obesity Drug Shows -19.8% Placebo-Adjusted BMI Reduction in Phase 3
Rhythm Pharmaceuticals announced positive topline results from its Phase 3 TRANSCEND trial of setmelanotide for acquired hypothalamic obesity. The...
IBIO-600 Primate Data Shows Extended Half-Life and Muscle Growth
iBio announced promising preclinical data for IBIO-600, a long-acting anti-myostatin antibody, and a first-in-class Activin E antibody, both targeting...
What Experts Are Saying About RWD in Clinical Trials
At the 2025 SCOPE Summit Conference, industry leaders gathered to discuss the integration of real-world data (RWD) into clinical...
TR1X Awarded $8M Grant for TRX103 GvHD Trial
Tr1X, a clinical-stage biopharmaceutical company, received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to...
Son-1010 Shows Strong Safety in Ovarian Cancer Treatment
Sonnet BioTherapeutics announced positive safety results for SON-1010, an IL-12 based immunotherapy, combined with atezolizumab in a Phase 1b/2a...
ARV-102: First-in-Human Data Shows Blood-Brain Barrier Penetration
Arvinas presented positive Phase 1 clinical trial data for ARV-102, a PROTAC degrader targeting LRRK2, a protein implicated in...
Anavex Life Sciences Announces Positive 4-Year Blarcamesine Results
Anavex Life Sciences announced positive data from its ATTENTION-AD trial, a long-term extension of a Phase 2b/3 study evaluating...